A Novel Putative Indicator of Irritable Bowel Syndrome: Erythrocyte Aggregation

被引：0

作者：

Abdullayeva, Gunel ^{[1
]}

机构：

[1] Akdeniz Univ, Fac Med, Dept Physiol, Antalya, Turkey

来源：

ACTA PHYSIOLOGICA | 2018年 / 225卷

关键词：

D O I：

暂无

中图分类号：

Q4 [生理学];

学科分类号：

071003 ;

摘要：

PC090

引用

页码：60 / 60

页数：1

共 50 条

[11] Novel pharmacological therapies for irritable bowel syndrome
Corsetti, Maura
Whorwell, Peter
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (07) : 807 - 815
[12] ERYTHROCYTE AGGREGATION INDEX - A NEW INDICATOR OF INFLAMMATORY BOWEL-DISEASE ACTIVITY
FABRY, TL
ZHANG, ZG
SACHAR, DB
CLINICAL RESEARCH, 1987, 35 (03): : A408 - A408
[13] Irritable bowel syndrome - Recent and novel therapeutic approaches
Andresen, Viola
Camilleri, Michael
DRUGS, 2006, 66 (08) : 1073 - 1088
[14] LUBIPROSTONE - A NOVEL TREATMENT FOR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
Owen, Richard T.
DRUGS OF TODAY, 2008, 44 (09) : 645 - 652
[15] Linaclotide: A Novel Approach to the Treatment of Irritable Bowel Syndrome
Wensel, Terri M.
Luthin, David R.
ANNALS OF PHARMACOTHERAPY, 2011, 45 (12) : 1535 - 1543
[16] High prevalence of putative slow EPSP dysfunction in irritable bowel syndrome (IBS)
Simren, M
Thomas, EA
Bornstein, JC
Sjovall, H
GASTROENTEROLOGY, 2004, 126 (04) : A225 - A225
[17] Probiotics and irritable bowel syndrome: Rationale, putative mechanisms, and evidence of clinical efficacy
Camilleri, M
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2006, 40 (03) : 264 - 269
[18] IRRITABLE BOWEL SYNDROME - PRINCIPLES AND NOVEL TREATMENT OPTIONS
Hellstrom, P. M.
Webb, D. -L.
DRUGS OF THE FUTURE, 2011, 36 (09) : 669 - 675
[19] Irritable bowel syndrome
Joel A. Sach
Lin Chang
Current Treatment Options in Gastroenterology, 2002, 5 (4) : 267 - 278
[20] Irritable Bowel Syndrome
Camilleri, M.
NEUROGASTROENTEROLOGY AND MOTILITY, 2012, 24 : 12 - 13

← 1 2 3 4 5 →